Originally initiated in July 2018, the partnership combines DCprime’s proprietary DCOne relapse vaccine platform and Glycotope’s highly specific antitumour antibody platform with the aim of developing novel immunotherapeutic approaches in oncology.
Under the expanded agreement, a therapeutic antibody programme has been selected from Glycotope’s portfolio that will be further evaluated in preclinical studies to potentially treat a broad range of solid tumours.
“Today’s agreement further exemplifies our commitment to develop novel cancer immunotherapies based on partnerships, in addition to pioneering the relapse vaccine paradigm. Our relationship with Glycotope has matured and brought forward a very promising program, potentially leading to a highly differentiated novel combination therapy towards solid tumors,” commented Erik Manting, CEO of DCprime.
“We are delighted to expand our collaboration with DCprime and to see one of our antibody programmes move forward in a novel combination therapy approach with a cancer vaccine based on the DCOne platform,” said Henner Kollenberg, Managing Director of Glycotope GmbH.
“Glycotope has developed a growing pipeline of high-value cancer therapies and today’s announcement further highlights the promising product opportunities for monotherapeutic or combinational approaches offered by our portfolio.”
